A Reference Material for Harmonisation of D-Dimer Assays

Willem Nieuwenhuizen

doi:10.1055/s-0038-1656098

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 77(05): 1031-1033
DOI: 10.1055/s-0038-1656098

Scientific and Standardization Committee Communication

Schattauer GmbH Stuttgart

A Reference Material for Harmonisation of D-Dimer Assays

Willem Nieuwenhuizen

The Gaubius Laboratory, Leiden, The Netherlands, on behalf of the Fibrinogen Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis

› Author Affiliations

Abstract

PDF Download

Summary

The term “D-dimer assay” suggests, that these assays report the concentrations of the end-stage degradation product of crosslinked fibrin. This hardly occurs in patients. Degradation products of crosslinked fibrin rather occur with a wide range of molecular weights, and comprise various numbers of the D-dimer motif. Moreover, the numerical values obtained with different “D-dimer” assays vary widely. The variations are probably due to differences in reactivity of the various monoclonal antibodies used with the various D-dimer containing degradation products as they occur in patients; and to the various calibrators with a value assigned by the manufacturers. For the reasons indicated above a calibrator in the strict sense (e.g. pure D-dimer) is not feasible. This study shows that: it appears feasible to generate a conversion factor for each of the “D-dimer” assays studied, which will make the widely varying results obtained with these kits comparable; that the conversion factors can be based on a pool of real patient samples; and that the conversion factors are pool-independent.

The next and final step in this study is to prepare and make available an international reference material for use by manufacturers and others facing a comparison problem. This is being carried out, in collaboration with the NIBSC (Dr. P. Gaffney), and the material is expected to be available in early 1997.

PDF (871 kb)

References

References
1 Kudryk B, Reuterby J, Blombäck B. Adsorption of plasmic fragment D to thrombin modified fibrinogen-Sepharose. Thromb Res 1973; 2: 297-304
2 Blombäck B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501
3 Budzynski AZ, Olexa SA, Pandya BV. Fibrin polymerisation sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 1983; 408: 301-314
4 Hermans J, McDonagh J. Fibrin: structure and interaction. Semin Thromb Haemostas 1982; 8: 11-24
5 Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS. The covalent structure of factor XIII_a-crosslinked fibrinogen fibrils. J Struct Biol 1995; 115: 88-101
6 Gaffney PJ. FDP. Lancet 1972; 02: 1422
7 Francis CW, Marder VJ, Barlow GH. Plasmin degradation of crosslinked fibrin. J Clin Invest 1980; 66: 1033-1043
8 Kroneman H, Nieuwenhuizen W, Knot EAR. Monoclonal antibody-based plasma assays for fibrin(ogen) and derivatives, and their clinical relevance. Blood Coagul Fibrinol 1990; 1: 91-111
9 Koopman J, Haverkate F, Koppert PW, Nieuwenhuizen W, Brommer EJP, van der Werf WGC. New immunoassay for fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84
10 Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: Analysis of standardization issues and target antigens in plasma. Brit J Haematol 1995; 90: 187-194